Dr. Markowski on phase 3 trial of sabizabulin (VERU-111) in mCRPC

Mark Christopher Markowski, MD, PhD, discusses a phase 3 trial exploring the novel oral cytoskeletal disruptor sabizabulin (VERU-111) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on at least 1 androgen receptor targeting agent. The study, which is currently recruiting (NCT04844749), was launched following positive phase 1b/2 data. Markowski, an assistant professor of Oncology at Johns Hopkins Medicine, was the lead study author on the phase 1b/2 study, data from which were shared at the 2021 ASCO Annual Meeting. (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056)